FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1988853287> ?p ?o ?g. }

• W1988853287 endingPage "332" @default.
• W1988853287 startingPage "321" @default.
• W1988853287 abstract "Transient receptor potential vanilloid 1 (TRPV1) is a cation-permeable ion channel found in the peripheral and central nervous systems. The membrane surface expression of TRPV1 is known to occur in neuronal cell bodies and sensory neuron axons. TRPV1 receptors are also expressed in the hippocampus, the main epileptogenic region in the brain. Although, previous studies implicate TRPV1 channels in the generation of epilepsy, suppression of ongoing seizures by TRPV1 antagonists has not yet been attempted. Here, we evaluate the role of TRPV1 channels in the modulation of epileptiform activity as well as the anti-convulsant properties of capsazepine (CZP), an established TRPV1 competitive antagonist, using in vitro and in vivo models. To this end, we used 4-aminopyridine (4-AP) to trigger seizure-like activity. We found that CZP suppressed 4-AP induced epileptiform activity in vitro (10-100μM) and in vivo (50mg/kg s.c.). In contrast, capsaicin enhanced 4-AP induced epileptiform activity in vitro (1-100μM) and triggered bursting activity in vivo (100μM dialysis perfusion), which was abolished by the TRPV1 antagonist CZP. To further investigate the mechanisms of TRPV1 modulation, we studied the effect of capsaicin and CZP on evoked potentials. Capsaicin (1-100μM) and CZP (10-100μM) increased and decreased, respectively, the amplitude of extracellular field evoked potentials in a concentration-dependent manner. Additional in vitro studies showed that the effect of the TRPV1 blocker on evoked potentials was similar whether the response was orthodromic or antidromic, suggesting that the effect involves interference with membrane depolarization on cell bodies and axons. The fact that CZP could act directly on axons was confirmed by decreased amplitude of the compound action potential and by an increased delay of both the antidromic potentials and the axonal response. Histological studies using transgenic mice also show that, in addition to the known neural expression, TRPV1 channels are widely expressed in alvear oligodendrocytes in the hippocampus. Taken together, these results indicate that activation of TRPV1 channels leads to enhanced excitability, while their inhibition can effectively suppress ongoing electrographic seizures. These results support a role for TRPV1 channels in the suppression of convulsive activity, indicating that antagonism of TRPV1 channels particularly in axons may possibly be a novel target for effective acute suppression of seizures." @default.
• W1988853287 created "2016-06-24" @default.
• W1988853287 creator A5012103598 @default.
• W1988853287 creator A5017929098 @default.
• W1988853287 creator A5053192844 @default.
• W1988853287 creator A5087674011 @default.
• W1988853287 date "2013-12-01" @default.
• W1988853287 modified "2023-10-18" @default.
• W1988853287 title "TRPV1 antagonist capsazepine suppresses 4-AP-induced epileptiform activity in vitro and electrographic seizures in vivo" @default.
• W1988853287 cites W1623815617 @default.
• W1988853287 cites W1964358846 @default.
• W1988853287 cites W1965593592 @default.
• W1988853287 cites W1966917036 @default.
• W1988853287 cites W1968366571 @default.
• W1988853287 cites W1981582879 @default.
• W1988853287 cites W1985441860 @default.
• W1988853287 cites W1997327749 @default.
• W1988853287 cites W1999236018 @default.
• W1988853287 cites W2004213712 @default.
• W1988853287 cites W2005312899 @default.
• W1988853287 cites W2034831698 @default.
• W1988853287 cites W2040664792 @default.
• W1988853287 cites W2042489135 @default.
• W1988853287 cites W2044632947 @default.
• W1988853287 cites W2053251168 @default.
• W1988853287 cites W2062963816 @default.
• W1988853287 cites W2064910025 @default.
• W1988853287 cites W2066559312 @default.
• W1988853287 cites W2069404682 @default.
• W1988853287 cites W2073533991 @default.
• W1988853287 cites W2073606727 @default.
• W1988853287 cites W2075125615 @default.
• W1988853287 cites W2077830428 @default.
• W1988853287 cites W2082014695 @default.
• W1988853287 cites W2083260368 @default.
• W1988853287 cites W2090617423 @default.
• W1988853287 cites W2091796838 @default.
• W1988853287 cites W2094326590 @default.
• W1988853287 cites W2099414466 @default.
• W1988853287 cites W2117845809 @default.
• W1988853287 cites W2138912696 @default.
• W1988853287 cites W2157174760 @default.
• W1988853287 cites W2222396702 @default.
• W1988853287 doi "https://doi.org/10.1016/j.expneurol.2013.10.010" @default.
• W1988853287 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4104534" @default.
• W1988853287 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24145133" @default.
• W1988853287 hasPublicationYear "2013" @default.
• W1988853287 type Work @default.
• W1988853287 sameAs 1988853287 @default.
• W1988853287 citedByCount "79" @default.
• W1988853287 countsByYear W19888532872014 @default.
• W1988853287 countsByYear W19888532872015 @default.
• W1988853287 countsByYear W19888532872016 @default.
• W1988853287 countsByYear W19888532872017 @default.
• W1988853287 countsByYear W19888532872018 @default.
• W1988853287 countsByYear W19888532872019 @default.
• W1988853287 countsByYear W19888532872020 @default.
• W1988853287 countsByYear W19888532872021 @default.
• W1988853287 countsByYear W19888532872022 @default.
• W1988853287 countsByYear W19888532872023 @default.
• W1988853287 crossrefType "journal-article" @default.
• W1988853287 hasAuthorship W1988853287A5012103598 @default.
• W1988853287 hasAuthorship W1988853287A5017929098 @default.
• W1988853287 hasAuthorship W1988853287A5053192844 @default.
• W1988853287 hasAuthorship W1988853287A5087674011 @default.
• W1988853287 hasBestOaLocation W19888532872 @default.
• W1988853287 hasConcept C12554922 @default.
• W1988853287 hasConcept C150903083 @default.
• W1988853287 hasConcept C155164980 @default.
• W1988853287 hasConcept C160145004 @default.
• W1988853287 hasConcept C169760540 @default.
• W1988853287 hasConcept C170493617 @default.
• W1988853287 hasConcept C185263204 @default.
• W1988853287 hasConcept C185592680 @default.
• W1988853287 hasConcept C207001950 @default.
• W1988853287 hasConcept C2776885963 @default.
• W1988853287 hasConcept C2780051329 @default.
• W1988853287 hasConcept C2780071552 @default.
• W1988853287 hasConcept C2780922449 @default.
• W1988853287 hasConcept C55493867 @default.
• W1988853287 hasConcept C83743174 @default.
• W1988853287 hasConcept C86803240 @default.
• W1988853287 hasConcept C96376961 @default.
• W1988853287 hasConcept C98274493 @default.
• W1988853287 hasConceptScore W1988853287C12554922 @default.
• W1988853287 hasConceptScore W1988853287C150903083 @default.
• W1988853287 hasConceptScore W1988853287C155164980 @default.
• W1988853287 hasConceptScore W1988853287C160145004 @default.
• W1988853287 hasConceptScore W1988853287C169760540 @default.
• W1988853287 hasConceptScore W1988853287C170493617 @default.
• W1988853287 hasConceptScore W1988853287C185263204 @default.
• W1988853287 hasConceptScore W1988853287C185592680 @default.
• W1988853287 hasConceptScore W1988853287C207001950 @default.
• W1988853287 hasConceptScore W1988853287C2776885963 @default.
• W1988853287 hasConceptScore W1988853287C2780051329 @default.
• W1988853287 hasConceptScore W1988853287C2780071552 @default.
• W1988853287 hasConceptScore W1988853287C2780922449 @default.
• W1988853287 hasConceptScore W1988853287C55493867 @default.

• next